EpiPen

In prepared congressional testimony, Mylan CEO Heather Bresch is defending the cost for life-saving EpiPens and does not suggest any plans for lowering those prices. Bresch’s testimony was released by the House Oversight and Government Reform Committee ahead of her appearance before the panel, today.